CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 50 enrolled
Drug / intervention
Regadenosondrug
Likely dose
Regadenoson 400 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00881218
NCT00881218Early Ph 1Completed
CompareCT.gov

Feasibility of Detecting Myocardial Ischemia by First-pass Contrast MRI Using Regadenoson

Washington University School of Medicine·interventional·Posted Apr 15, 2009·Updated Apr 10, 2012

In Brief

A Early Phase 1 clinical trial evaluating Regadenoson for Ischemic Heart Disease. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart. The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce coronary vasodilatation and demonstrate myocardial ischemia during first-pass perfusion cardiac MRI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Heart Disease
CountriesUnited States
CollaboratorsAstellas Pharma US, Inc.

Timeline

Early Ph 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 15, 2009
Enrollment StartJun 1, 2009
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.2 years ago

Interventions

Regadenosondrug

Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.